- Home
- BTAI vs APRE Comparison
BTAI vs APRE Comparison
Compare BTAI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- APRE
- Stock Information
- Founded
- BTAI 2017
- APRE 2006
- Country
- BTAI United States
- APRE United States
- Employees
- BTAI N/A
- APRE N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTAI Health Care
- APRE Health Care
- Exchange
- BTAI Nasdaq
- APRE Nasdaq
- Market Cap
- BTAI 18.1M
- APRE 15.8M
- IPO Year
- BTAI 2018
- APRE 2019
- Fundamental
- Price
- BTAI $0.34
- APRE $3.85
- Analyst Decision
- BTAI Buy
- APRE Strong Buy
- Analyst Count
- BTAI 4
- APRE 2
- Target Price
- BTAI $2.81
- APRE $15.50
- AVG Volume (30 Days)
- BTAI 1.3M
- APRE 33.0K
- Earning Date
- BTAI 03-11-2025
- APRE 11-07-2024
- Dividend Yield
- BTAI N/A
- APRE N/A
- EPS Growth
- BTAI N/A
- APRE N/A
- EPS
- BTAI N/A
- APRE N/A
- Revenue
- BTAI $2,276,000.00
- APRE $1,310,839.00
- Revenue This Year
- BTAI $131.23
- APRE $134.21
- Revenue Next Year
- BTAI $45.79
- APRE N/A
- P/E Ratio
- BTAI N/A
- APRE N/A
- Revenue Growth
- BTAI 83.25
- APRE 130.31
- 52 Week Low
- BTAI $0.30
- APRE $2.15
- 52 Week High
- BTAI $4.17
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- BTAI 42.14
- APRE 56.63
- Support Level
- BTAI $0.33
- APRE $3.34
- Resistance Level
- BTAI $0.39
- APRE $3.83
- Average True Range (ATR)
- BTAI 0.06
- APRE 0.42
- MACD
- BTAI -0.00
- APRE 0.01
- Stochastic Oscillator
- BTAI 9.27
- APRE 36.04
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.